Full Text View
Tabular View
No Study Results Posted
Related Studies
Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)
This study has been completed.
Study NCT00672659   Information provided by PharmaNeuroBoost N.V.
First Received: May 2, 2008   Last Updated: January 30, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Depression
Additional conditions recognized in this trial
Depressive Disorder
Depressive Disorder, Major
More general conditions related to this trial
Behavioral Symptoms
Mental Disorders
Mood Disorders
Interventions listed in this trial
Citalopram + Pipamperone
Citalopram
Additional drug interventions recognized in this trial
Dexetimide
Pipamperone
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Serotonin Uptake Inhibitors
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
PharmaNeuroBoost N.V.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services